Stock Price Quote

JAGSONPAL PHARMACEUTICALS LTD.

NSE : JAGSNPHARMBSE : 507789ISIN CODE : INE048B01027Industry : Pharmaceuticals & DrugsHouse : Jagsonpal
BSE341.55-4.9 (-1.41 %)
PREV CLOSE ( ) 346.45
OPEN PRICE ( ) 339.95
BID PRICE (QTY) 341.30 (1)
OFFER PRICE (QTY) 342.30 (1)
VOLUME 2938
TODAY'S LOW / HIGH ( )332.50 347.10
52 WK LOW / HIGH ( )270.05 513.9
NSE342.00-3.85 (-1.11 %)
PREV CLOSE( ) 345.85
OPEN PRICE ( ) 340.00
BID PRICE (QTY) 341.60 (10)
OFFER PRICE (QTY) 341.95 (2)
VOLUME 15391
TODAY'S LOW / HIGH( ) 334.00 348.60
52 WK LOW / HIGH ( )273.6 514.85
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 17-08 1978
Management Info
Harsha Raghavan - Chairman Manish Gupta - Managing Director
Registered Office

Address T 210 J,Shabpur Jat, ,
New Delhi,
Delhi-110049

Phone 011-46181100 / 46109900

Email cs@jagsonpal.com

Website www.jagsonpal.com

Registrars Details
MCS Ltd
F-65, ,Okhla Industrial Area,Phase - I,New Delhi
Listing : BSE, NSE, MCX

NEWS

24May Jagsonpal Pharmaceutical launches Indi
Jagsonpal Pharmaceutical has launched MemUp, India’s first hormone repla..
24May Jagsonpal Pharmaceutical shines on lau
Jagsonpal Pharmaceuticals is currently trading at Rs. 341.00, up by 7.70..
24May Jagsonpal Pharmaceuticals informs abou
In terms of regulation 30 of the SEBI (LODR) Regulations, 2015, Jagsonpa..
09Mar Jagsonpal Pharmaceuticals launches ‘Qu
Jagsonpal Pharmaceuticals has launched QueeZy-ER providing relief from N..
08Mar Jagsonpal Pharmaceutical launches Quee
Jagsonpal Pharmaceutical has launched QueeZy-ER providing relief from Na..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit35.4900000000001224.63
Gross Profit 45.3600000000001 298.69
Operating Profit 51.5600000000001323.46
Net Sales 434.862087.02

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  27878.30 (1.72%)
M.Cap ( in Cr)59219.15
Dr. Reddy's Lab (BSE)
peergroup  6753.00 (1.72%)
M.Cap ( in Cr)112776.88
Torrent Pharma (BSE)
peergroup  3033.00 (2.87%)
M.Cap ( in Cr)101922.84
Alkem Laboratories (BSE)
peergroup  5219.15 (1.58%)
M.Cap ( in Cr)62114.02
Orchid Pharma (BSE)
peergroup  1374.70 (5.87%)
M.Cap ( in Cr)7097.89

Shareholding Pattern

PROMOTERS 68.04%
NON-INSTITUTION 30.01%
FI/BANKS/INSURANCE 0%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%
FII 0%

About Jagsonpal Pharmaceuticals Ltd.

Jagsonpal Pharmaceuticals Ltd. was incorporated in the year 1978. Its today's share price is 341.55. Its current market capitalisation stands at Rs 909.46 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2571.62 Cr and Total Income of Rs.2424.48 Cr. The company's management includes Prithipal Singh Kochhar, Rajpal Singh, Manish Gupta, Radhika Madhukar Dudhat, Pallavi Dinodia Gupta, Debasis Bikash Nandy, Harsha Raghavan, Abhishek Joshi.

It is listed on the BSE with a BSE Code of 507789 , NSE with an NSE Symbol of JAGSNPHARM and ISIN of INE048B01027. It's Registered office is at T 210 J,Shabpur Jat, New Delhi-110049, Delhi. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are HL Bansal & Co, PP Thukral & Co, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.